The Association of Apolipoprotein in the Risk of ST-elevation Myocardial Infarction in Patients with Documented Coronary Artery Disease

Overview

Journal Int J Cardiol Cardiovasc Risk Prev

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 17

PMID 37455789

Authors

Astuti Giantini

Nur Gifarani Pratiwi

Renan Sukmawan

Joedo Prihartono

Suzanna Immanuel

Merci Monica Pasaribu

Sri Suryo Adiyanti

Yusuf Bahasoan

Affiliations

Soon will be listed here.

Abstract

Introduction: Cardiovascular disease (CVD) is the number one cause of death worldwide, in this case, acute coronary syndrome (ACS) or acute myocardial infarction (AMI) that developed from coronary artery disease (CAD). Several risk factors contribute to AMI. Non-modifiable risk factors are age, sex, race, and family history. Modifiable risk factors include dyslipidemia, hypertension, smoking, diabetes mellitus, as well as recent factors that are considered more specific such as homocysteine, lipoprotein a [Lp(a)], high sensitivity C- reactive protein (hs-CRP), and apolipoprotein. This study aimed to determine the role of apolipoprotein as a risk factor for STEMI.

Methods: This study combines three epidemiological designs: a descriptive and cross-sectional correlative study with 62 STEMI patients at the National Cardiovascular Center Harapan Kita and a comparative study of 62 STEMI patients and 20 non-ACS CAD patients at the Universitas Indonesia Hospital.

Results And Conclusion: The descriptive study showed the level of apoB 80.71 ± 28.3, apoA1 104.93 ± 27.8, apoB/apoA1 ratio 0.78 ± 0.22, and Lp(a) 6.85 (1.0-48.1). ApoB moderately correlates with LDLc (p < 0.001; r = 0.571). ApoA1 weakly correlates with HDLc (p = 0.005; r = 0.379). In comparative study, there were significant differences between the STEMI and non-ACS CAD groups on apoA1 (104.93 ± 27.8 vs. 137.48 ± 26.46), apoB/apoA1 ratio (0.78 ± 0.22 vs. 0.59 ± 0.15), and hs-CRP (2.88 [0.4-215] vs. 0.73 [0.15-8.9]). Multivariate analysis showed that the most significant risk factors for STEMI in this study were hypertension for modifiable factors and apoA1 for apolipoprotein. The apoA1 and apoB/apoA1 ratio examination can be suggested for people who have experienced plaque formation and are at risk for myocardial infarction.

Citing Articles

The Role of Pro-Opiomelanocortin Derivatives in the Development of Type 2 Diabetes-Associated Myocardial Infarction: Possible Links with Prediabetes.

Gumede N, Khathi A Biomedicines. 2024; 12(2).

PMID: 38397916 PMC: 10887103. DOI: 10.3390/biomedicines12020314.

References

Fruchart J, Nierman M, Stroes E, Kastelein J, Duriez P . New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004; 109(23 Suppl 1):III15-9. DOI: 10.1161/01.CIR.0000131513.33892.5b. View

Bodde M, Hermans M, Jukema J, Schalij M, Lijfering W, Rosendaal F . Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol. 2018; 108(5):520-538. PMC: 6484771. DOI: 10.1007/s00392-018-1381-5. View

Li W, Liu X, Huang C, Liu L, Tan X, Wang X . The loss-of-function mutation of CETP affects HDLc levels but not ApoA1 in patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis. 2020; 31(2):602-607. DOI: 10.1016/j.numecd.2020.10.019. View

G H, Rao V, Kakkar V . Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol. 2011; 2011:274629. PMC: 3065911. DOI: 10.1155/2011/274629. View

Biswas S, Ghoshal P, Mandal S, Mandal N . Association of low-density lipoprotein particle size and ratio of different lipoproteins and apolipoproteins with coronary heart disease. J Cardiol. 2008; 52(2):118-26. DOI: 10.1016/j.jjcc.2008.06.005. View

Budoff M, Gul K . Expert review on coronary calcium. Vasc Health Risk Manag. 2008; 4(2):315-24. PMC: 2496978. DOI: 10.2147/vhrm.s1160. View

Kaneva A, Potolitsyna N, Bojko E, Odland J . The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers. 2015; 2015:591454. PMC: 4380097. DOI: 10.1155/2015/591454. View

Tsimikas S, Hall J . Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012; 60(8):716-21. DOI: 10.1016/j.jacc.2012.04.038. View

Jensen M, Chiuve S, Rimm E, Dethlefsen C, Tjonneland A, Joensen A . Obesity, behavioral lifestyle factors, and risk of acute coronary events. Circulation. 2008; 117(24):3062-9. DOI: 10.1161/CIRCULATIONAHA.107.759951. View

10.

Cegla J, France M, Marcovina S, Neely R . Lp(a): When and how to measure it. Ann Clin Biochem. 2020; 58(1):16-21. PMC: 7791270. DOI: 10.1177/0004563220968473. View

11.

Ansell B, Watson K, Fogelman A, Navab M, Fonarow G . High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005; 46(10):1792-8. DOI: 10.1016/j.jacc.2005.06.080. View

12.

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

13.

Kim S, Kang H, Jhon M, Kim J, Lee J, Walker A . Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Front Psychiatry. 2019; 10:103. PMC: 6413672. DOI: 10.3389/fpsyt.2019.00103. View

14.

Suh S, Park H, Kim S, Bae J, Tan A, Chung H . Smaller Mean LDL Particle Size and Higher Proportion of Small Dense LDL in Korean Type 2 Diabetic Patients. Diabetes Metab J. 2011; 35(5):536-42. PMC: 3221030. DOI: 10.4093/dmj.2011.35.5.536. View

15.

Yaseen R, El-Leboudy M, El-Deeb H . The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome. Egypt Heart J. 2021; 73(1):24. PMC: 7966664. DOI: 10.1186/s43044-021-00150-z. View

16.

Fadini Reis Brunori E, Lopes C, Cavalcante A, Santos V, de Lima Lopes J, de Barros A . Association of cardiovascular risk factors with the different presentations of acute coronary syndrome. Rev Lat Am Enfermagem. 2014; 22(4):538-46. PMC: 4292641. DOI: 10.1590/0104-1169.3389.2449. View

17.

Walldius G, Jungner I . Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis. 2007; 17(8):565-71. DOI: 10.1016/j.numecd.2007.02.010. View

18.

Ahmed M, Byrne R, Pazderska A, Segurado R, Guo W, Gunness A . HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study. Diabetologia. 2020; 64(3):656-667. DOI: 10.1007/s00125-020-05320-3. View

19.

Giantini A, Timan I, Dharma R, Sukmawan R, Setiabudy R, Alwi I . The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. Front Cardiovasc Med. 2023; 9:1027892. PMC: 9944402. DOI: 10.3389/fcvm.2022.1027892. View

20.

Benn M, Nordestgaard B, Jensen G, Tybjaerg-Hansen A . Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2006; 27(3):661-70. DOI: 10.1161/01.ATV.0000255580.73689.8e. View